Literature DB >> 28845508

Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension.

Christian Ott1, Christoph Kopp1, Anke Dahlmann1, Axel Schmid2, Peter Linz1, Alexander Cavallaro2, Matthias Hammon2, Tilmann Ditting1, Roland Veelken1, Michael Uder2, Jens Titze3, Roland E Schmieder4.   

Abstract

OBJECTIVES: Renal denervation (RDN) has been introduced for reducing blood pressure (BP) in treatment-resistant hypertension (TRH). The precise mechanism how RDN exerts its BP-lowering effects are not yet fully understood. It is widely accepted that sodium (Na+) plays a crucial role in the pathogenesis of hypertensive disease. However, there is increasing evidence of osmotically inactive Na+ storage. We investigated the impact of RDN on Na+ homeostasis using estimation of salt intake, and measurement of tissue Na+ content.
METHODS: In a study 41 patients with TRH (office BP ≥140/90 mmHg and diagnosis confirmed by 24-h ambulatory BP monitoring) underwent RDN. Tissue Na+ content was assessed non-invasively with 3.0 T magnetic resonance imaging before and 6 months after RDN. In addition, 24-h urinary Na+ excretion as an estimate of salt intake and spot urine Na+/K+ excretion were assessed. The study was registered at http://www.clinicaltrials.gov (ID: NCT01687725).
RESULTS: There was a significant fall in BP (office: -17 ± 20/-10 ± 12 mmHg; 24-h: -11 ± 13/-6 ± 9 mmHg, all p < 0.001) 6 months after RDN. In contrast, tissue Na+ content of the muscle (20.1 ± 3.9 vs. 20.7 ± 4.0 mmol/L, p = 0.229) and skin (24.4 ± 6.5 vs. 24.8 ± 6.6 mmol/L, p = 0.695) did not change after RDN. Moreover, there was also no change in salt intake after RDN, whereas Na+/K+ ratio only acutely increased.
CONCLUSIONS: Although RDN resulted in a substantial reduction of BP, tissue Na+ content of the muscle and skin was not mobilized and reduced. These data indicate that the BP reduction after RDN is unrelated to Na+ homeostasis.

Entities:  

Keywords:  Hypertension; Magnetic resonance imaging; Nervous system; Renal denervation; Sodium; Sympathetic

Mesh:

Substances:

Year:  2017        PMID: 28845508     DOI: 10.1007/s00392-017-1156-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  40 in total

Review 1.  Molecular mechanisms of human hypertension.

Authors:  R P Lifton; A G Gharavi; D S Geller
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Extrarenal Na+ balance, volume, and blood pressure homeostasis in intact and ovariectomized deoxycorticosterone-acetate salt rats.

Authors:  Jens Titze; Friedrich C Luft; Katharina Bauer; Peter Dietsch; Rainer Lang; Roland Veelken; Hubertus Wagner; Kai-Uwe Eckardt; Karl F Hilgers
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

3.  European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults.

Authors:  Eoin O'Brien; Neil Atkins; George Stergiou; Nikos Karpettas; Gianfranco Parati; Roland Asmar; Yutaka Imai; Jiguang Wang; Thomas Mengden; Andrew Shennan
Journal:  Blood Press Monit       Date:  2010-02       Impact factor: 1.444

Review 4.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney.

Authors:  Gerald F DiBona
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09       Impact factor: 3.619

5.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

6.  Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension.

Authors:  Guido Grassi; Gino Seravalle; Gianmaria Brambilla; Claudio Pini; Marina Alimento; Rita Facchetti; Domenico Spaziani; Cesare Cuspidi; Giuseppe Mancia
Journal:  Int J Cardiol       Date:  2014-10-18       Impact factor: 4.164

7.  ESH position paper: renal denervation - an interventional therapy of resistant hypertension.

Authors:  Roland E Schmieder; Josep Redon; Guido Grassi; Sverre E Kjeldsen; Giuseppe Mancia; Krzysztof Narkiewicz; Gianfranco Parati; Luis Ruilope; Philippe van de Borne; Costas Tsioufis
Journal:  J Hypertens       Date:  2012-05       Impact factor: 4.844

8.  Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation.

Authors:  Jason D Foss; Gregory D Fink; John W Osborn
Journal:  Hypertension       Date:  2013-02-04       Impact factor: 10.190

9.  Renal denervation in hypertensive patients not on blood pressure lowering drugs.

Authors:  Rosa L De Jager; Margreet F Sanders; Michiel L Bots; Melvin D Lobo; Sebastian Ewen; Martine M A Beeftink; Michael Böhm; Joost Daemen; Oliver Dörr; Dagmara Hering; Felix Mahfoud; Holger Nef; Christian Ott; Manish Saxena; Roland E Schmieder; Markus P Schlaich; Wilko Spiering; Pim A L Tonino; Willemien L Verloop; Eva E Vink; Evert-Jan Vonken; Michiel Voskuil; Stephen G Worthley; Peter J Blankestijn
Journal:  Clin Res Cardiol       Date:  2016-04-22       Impact factor: 5.460

Review 10.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Authors:  Felix Mahfoud; Roland E Schmieder; Michel Azizi; Atul Pathak; Horst Sievert; Costas Tsioufis; Thomas Zeller; Stefan Bertog; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Sebastian Ewen; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Melvin D Lobo; Chaim Lotan; Thomas Felix Lüscher; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Faisal Sharif; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

View more
  6 in total

1.  Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension.

Authors:  Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach
Journal:  Clin Res Cardiol       Date:  2019-04-06       Impact factor: 5.460

2.  Patient preference for therapies in hypertension: a cross-sectional survey of German patients.

Authors:  Roland E Schmieder; Karin Högerl; Susanne Jung; Peter Bramlage; Roland Veelken; Christian Ott
Journal:  Clin Res Cardiol       Date:  2019-04-02       Impact factor: 5.460

3.  Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension.

Authors:  Martin Steinmetz; Dominik Nelles; Jutta Weisser-Thomas; Christian Schaefer; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2018-04-11       Impact factor: 5.460

4.  FIFA World Cup 2018: effect of emotional stress on conventional heart rate variability metrics.

Authors:  Wolfgang Hamm; Viktoria Bogner-Flatz; Axel Bauer; Stefan Brunner
Journal:  Clin Res Cardiol       Date:  2019-08-06       Impact factor: 5.460

5.  Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.

Authors:  Manuel Wallbach; Ellen Born; Deborah Kämpfer; Stephan Lüders; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Clin Res Cardiol       Date:  2019-08-06       Impact factor: 5.460

6.  Neurogenic substance P-influences on action potential production in afferent neurons of the kidney?

Authors:  Kristina Rodionova; Karl F Hilgers; Peter Linz; Johannes Schätzl; Giulia Raschke; Christian Ott; Roland E Schmieder; Mario Schiffer; Kerstin Amann; Roland Veelken; Tilmann Ditting
Journal:  Pflugers Arch       Date:  2021-03-30       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.